MIVT.OB~~Sector: Healthcare~~Industry: Medical Equipment & Supplies

[setravis]

an setravis....hoorah !

52wk Range: 0.35 - 1.45
Volume: 1,450,758
Avg Vol (3m): 252,920

Technicals
Last Price Quote is:
36.35%above 13-day MA
61.35%above 50-day MA
RS Rating: N/A 

Fundamentals
Key Data:
Market Cap (M): $42.18 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: N/A

[setravis]

Press Release Source: MIV Therapeutics, Inc.


Investrend Affiliate SISM Research 'Morning Note' Reiterates MIV Therapeutics 'Buy/4' Rating, $2.50 Target Valuation, Citing Plans To Introduce New Products In Key Global Markets Next Quarter
Monday December 18, 10:03 am ET 
MIVT announced Biosync's seven new CE Mark-certified cardiovascular stents and related products to be sold in India, then Europe, Asia and Latin America


NEW YORK--(BUSINESS WIRE)--(Investrend Research Syndicate) Ernest C. Schlotter, a senior analyst with Investrend affiliate SISM Research and a four star analyst according to StarMine, has reiterated his "Buy/4" Rating and $2.50 12-month Target Valuation for MIV Therapeutics, Inc. (OTCBB: MIVT - News) in a "Morning Note."


The full Research Note, including important disclosures and disclaimers, is available at http://www.sism.com and http://www.investrendresearch.com. In it, analyst Schlotter said:

"Last Thursday MIVT announced that Biosync now has a portfolio of seven new CE Mark-certified cardiovascular stents and related products that can be sold in Europe and other key markets around the world. The launch of Biosync products opens the door for MIVT's HAp-coated DES and other associated interventional cardiology products, once CE Mark-certified.

"Biosync has strong relations in India and around the world with established distribution networks. The angioplasty market in India ($60M) offers huge opportunities for MIVT. Approx. 70,000 angioplasties are performed every year in India, accounting for only 0.007% of the one billion strong ageing populations. MIVT will primarily targeting the DES market outside the U.S. is estimated to reach $4 billion in 2008."

SISM Research believes that the Biosync acquisition will help the Company in a short time to realize the full potential of its earning power and further drive its valuation. At a market valuation of only $56M the Research Company believes that MIVT is significantly undervalued.

MIV Therapeutics is paying SISM Research $2,250 per month over a two-year period solely to ensure independent coverage."

SISM Research, based in Zurich, Switzerland, is a private investment research firm offering high-quality, independent, fundamental research on public companies since 1995. SISM Research writes, publishes and distributes research coverage on micro- to small-cap public companies trading on the OTC, NASDAQ and AMEX.

This coverage is geared toward institutional and individual investors in both North America and in German-speaking Europe, a market that represents more than 100 million people. SISM Research is a content provider to Thomson Financials OneAnalytics/FirstCall and Investext, to Reuters Multex, Knobias and Investrend.

The full report, including important disclosures and disclaimers, is available at http://www.sism.com, http://www.investrendresearch.com, and at the company's InvestorPower Page accessible from http://www.investrend.com/company/list.asp?sPathParam=yes. Investors are advised to read those disclosures carefully before trading in the equities of any enrolled company.

Both SISM Research and Investrend Research subscribe to the "Standards for Independent Research Providers" at http://www.firstresearchconsortium.com, and MIVT's research will be enrolled for investor monitoring by the not-for-profit Shareholders Research Alliance, Inc. (http://www.shareholdersresearch.com).

Anyone interested in receiving alerts regarding MIV Therapeutics research should email [email protected] with "MIVT" in the subject line.

Forward-Looking Statements: Statements in this news release that are not historical facts are forward-looking statements that are subject to risks and uncertainties. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results.

Contact:
MIV Therapeutics, Inc.
Investor Relations
604-301-9545 ext. 14
Toll-free: 800-221-5108
http://www.mivtherapeutics.com/
or
Investrend Research Div.
Investrend Communications, Inc.
R. Hempel, 718-896-5060
[email protected]
www.investrendresearch.com

--------------------------------------------------------------------------------
Source: MIV Therapeutics, Inc.

[setravis]

A 61.8% Fibonacci retracement @ $0.62
Looks to be catching a bounce off the 200-day MA

52wk Range: 0.35 - 1.43
Volume: 404,477
Avg Vol (3m): 276,655

Technicals
Last Price Quote is:
0.31%above 13-day MA
21.35%above 50-day MA
RS Rating: N/A 

Fundamentals
Key Data:
Market Cap (M): $42.18 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: N/A

[rdemp52572]

I came across this company this weekend and liked everything I read about them.

"..."We feel very confident that fiscal year 2007 will be the most exciting and rewarding in MIVT's history," said Dr. Mark Landy. "We will leverage these funds to promote the various strategic initiatives that are currently positioning MIVT to capitalize on the growing international markets for stent technology..."

http://biz.yahoo.com/bw/070108/20070108005064.html?.v=1

If somebody like JNJ or BSX picked them up this could explode which is why I'm going to buy some at the open!

[rdemp52572]

MIV Therapeutics Announces Renowned Researcher to Detail Milestone Pre-Clinical Results at Prominent International Conference EuroPCR 2007

Tuesday May 22, 4:01 pm ET 

ATLANTA--MIV Therapeutics (OTCBB:MIVT - News; FWB:MIV), a leading developer of next generation biocompatible coatings and advanced drug delivery systems for Cardiovascular stents and other implantable medical devices, is pleased to announce that results from an animal trial comparing its proprietary polymer free Hydroxyapatite-coated drug-eluting cardiovascular stent to J&J's Cypher Stent will be presented at this weeks EuroPCR 2007 conference in Barcelona, Spain.

Dr Willem J. van der Giesen, MD, PhD from the Erasmus University Medical Center will make a presentation on next generation drug eluting stents, in which he will discuss the results of the 4 week porcine study, performed by the Department of Cardiology, Thoraxcenter, Erasmus University Medical Center in the Netherlands, an independent research organization.

The study indicated that three variations of MIVT's Hydroxyapatite-based Drug-Eluting stents were at least as effective as, and in some cases, better than one of the worlds leading drug-eluting cardiovascular stents produced by Johnson & Johnson (Cypher(TM)). These results provided the necessary data to advance the technology to human studies.

Hydroxyapatite, unlike polymer coatings, is naturally derived and found in such hard tissues and bioceramic materials as human bone and teeth. Research has indicated that MIVT's HAp coatings do not trigger the various adverse and inflammatory reactions that are often associated with implantation of polymer-coated stents and other foreign substances.

HAp coatings are also expected to reduce the risk of thrombogenic (blood clotting) events attributable in some instances to polymer-coated stents. Some of the most recent information presented at various conferences estimated that thrombogenicity was identified in at least 20,000 cases of implanted drug-eluting stents to-date, resulting in approximately 8,000 premature deaths.

EuroPCR is a major European event based on the exchanged of scientific information and education for interventional cardiologists.

http://biz.yahoo.com/bw/070522/20070522006185.html?.v=1

[setravis]

ANNOUNCES RESEARCH COLLABORATION: MIV Therapeutics (MIVT.OB) announced a research
collaboration with contributions in kind from both Smith & Nephew and MIV Therapeutics
to develop new coatings and drug delivery systems for orthopedic devices. The Companies have
programs in cardiology and orthopedics, and they will continue to evaluate additional opportunities
in different therapeutics areas.

[rdemp52572]

THREE MONTHS ENDED AUGUST 31, 2007 COMPARED TO AUGUST 31, 2006

Revenues. During the three months ended August 31, 2007, revenues from the sale of stents were $301,610 compared to nil for the same quarter of the prior year. Sales were attributed to stents sold by Biosync Scientific in India. There were no comparable sales by the Company for the prior year due the acquisition of Biosync Scientific in February 2007. Cost of goods sold during the quarter ended August 31, 2007 were $258,041 resulting in a gross profit of $43,569. There was no comparable data for the same quarter for the prior year.

http://biz.yahoo.com/e/071015/mivt.ob10-q.html

With TCT starting up this weekend this could be a very good couple of weeks!!!

http://www.tct2007.com/index.php

[rdemp52572]

Results of First-In-Man Study With MIVT Low Dose Polymer-Free Drug-Eluting Stent to Be Presented at TCT Conference
Company Presence at TCT to Include One Oral Presentation and Two Posters

ATLANTA, GA, Oct 16, 2007 (MARKET WIRE via COMTEX) -- MIV Therapeutics, Inc. (MIVT:miv therapeutics inc com

MIVT, (FRANKFURT: MIV), a leading developer of next-generation coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, announces that results of the first-in-man safety study with the Company's drug-eluting stent will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2007 conference, to be held October 20-25 at the Washington Convention Center in Washington, D.C.
Principal investigator Alexandre Abizaid, M.D., Ph.D., Chief of Coronary Intervention of Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil, will make the presentation titled, "The MIV Polymer-Free Hydroxyapatite-Coated Sirolimus-Eluting Stent: First-in-Man Angiographic and IVUS Follow-Up Results." Dr. Abizaid's presentation will take place on Sunday, October 21 in Room 152A at 3:03 p.m. Eastern time. It is part of a practical workshop titled "First-In-Man Experiences With Drug-Eluting Stents I and Passive and Active Stent Coatings" within the scientific symposia "Innovative Devices and Futuristic Concepts I: Novel Bare Metal and Drug-Eluting Stents."
"We are very pleased the findings of this important first-in-man study will be presented at such a prestigious medical conference. This 15-patient study was conducted very efficiently, and began with the first human implantation of our low dose polymer-free hydroxyapatite-coated drug-eluting stent in May of this year, and each patient was followed for four months," said Dr. Mark Landy, President of MIV Therapeutics. "We are looking forward to the largest-ever presence for MIV Therapeutics at the TCT conference, we believe that acceptance to present at this conference is an important recognition of the significance of our proprietary technology."
The MIV Therapeutics presence at the 2007 TCT conference also will include two posters:
Presented by Greg L. Kaluza, MD, PhD, Cardiovascular Research Foundation:
"Platelet Activation and Adhesion after Exposure to Nanofilm and Microporous Hydroxyapatite Stent Coating: An Ex-Vivo Study of Hydroxyapatite-Coated Stents Deployed in a Continuous Flow-Chamber Model."
Presented by Dr. Dorna Hakimimehr, Scientist MIVT:
"In-Vitro Evaluation of a Novel Dual-Drug Eluting Stent to Target Inflammation and Proliferation Following Stent Implantation."
Dr. Landy added, "Having completed a $12.55 million equity financing in July, we are looking forward to continuing on our path to commercialize a novel drug-eluting stent without the safety issues surrounding current polymer-based drug-eluting stents."

http://www.marketwatch.com/news/story/results-first-in-man-study-mivt-low/story.aspx?guid=%7BD6B81B1A%2D60DB%2D4A27%2D97FD%2D2B80C95C5296%7D&dist=TQP_Mod_pressN

[setravis]

MIVT.OB
MIV Therapeutics Comments on Sale
of SagaX to Focus on Cardiology Segment
MIV Therapeutics, Inc. (MIVT) has entered into a definitive Share Purchase
Agreement to sell all of its issued and outstanding shares of
SagaX Inc. in Israel for consideration of $4.0 million plus future royalties
on sales of 8.0%. The purchaser is Israeli-based Shimoco LLC,
which is owned and controlled by and Dr. Dov Shimon, the founder of
SagaX, who has resigned from his position on the company's Board of
Directors as a consequence of the entering into of the Share Purchase
Agreement. SagaX is principally engaged in the business of developing
a neuro-vascular embolic stent filter medical device, called an Anti
Embolic Protection Device. "This transaction is a win-win for all parties,"
commented Dr. Mark Landy, president of MIV Therapeutics. "The sale
of SagaX will allow MIV to better focus on its goal of being a leader in
the interventional cardiology space, and saves us in excess of $1.0 million
or more annually in development costs, while freeing up SagaX to
pursue other financing avenues." MIVT develops ultra thin, polymer-free
passive and drug-eluting coatings for cardiovascular stents and a broad
range of other implantable medical devices. The Company's proprietary
ultra-thin, hydroxyapatite (HAp) based polymer-free coating has demonstrated
excellent safety and biocompatibility in animal studies and
human clinical trials. Hydroxyapatite is a naturally occurring porous
material that makes up human bone mineral and the matrix of human
teeth and is widely used today as a bone substitute material and for
coatings on implantable fixation devices in orthopedic, dental and other
applications. Through a Collaborative Research Agreement (CRA)
with The University of British Columbia, the Company has received a
Canadian Government grant for its research program. Introduction of
new biocompatible polymer-free coatings is expected to provide an attractive
alternative to current polymer-based drug-eluting coatings especially
in the drug eluting stent market, where it is widely believed that
polymers are associated with an increase in undesirable side effects
that may be fatal. Last week, the Drugs Controller General of India, the
governmental agency with regulatory authority over medical products,
approved two of the Company's bare metal stents for manufacture and
sale in India. The GenX(TM) Stainless Steel Coronary Stent & Stent
System and the GenX(TM) CrCo Chromium Cobalt Coronary Stent &
Stent System along with the Company's additional angioplasty products
will be officially launched into the Indian market beginning December 5,
2007, through third party distributors. Dr. Landy noted, "This regulatory
achievement permits MIV Therapeutics' entree into one of the world's
fastest growing stent markets with a highly competitive offering, and
allows us to continue refining and increasing our manufacturing capability
as we advance the clinical development of our unique drug-eluting
stents using our advanced biocompatible coatings and drug delivery
technology."

[rdemp52572]

"This promotion is well-deserved recognition for the excellent progress Mark has made in advancing the commercialization of our technology, with the most recent achievement being strong data from our First-in-Man study of our drug eluting stent," commented Alan Lindsay.

http://biz.yahoo.com/iw/080107/0345446.html

Does this PR mean we'll being seeing another shortly announcing the good news?

[setravis]

MIVT's CEO Discusses Company's
Next Generation of Drug Eluting Stents...

MIV Therapeutics Inc (MIVT) develops a line of advanced bio-pa1ge
compatible coatings for passive and drug-eluting applications
on cardiovascular stents, as well as for a broad range of other
implantable medical devices.
The Company's ultra-thin coating formulation is designed to protect surrounding
tissue from potentially harmful interactions with bare metallic stents. This
coating platform is derived from hydroxyapatite (HAp), an organic material that has demonstrated
excellent in vivo safety and biocompatibility. Hydroxyapatite is a porous material that
makes up the bone mineral and matrix of teeth, and is widely used today as a bone substitute
material and for coatings on implantable fixation devices in orthopedic, dental and other applications.
MIV Therapeutics recently began enrollment in a registration trial for its VESTAsync(TM)
polymer-free drug-eluting stent. Based on excellent nine-month human safety and efficacy
data, the Company has accelerated its original timeline for the VESTASYNC II trial, which is
designed to test the efficacy of the VESTAsync(TM) in a sufficient number of patients to form
the basis of a regulatory filing for marketing approval in Europe. It is anticipated that these
patient data will also be part of an eventual submission to the U.S. FDA.
Dr. Mark Landy, President and CEO of MIV Therapeutics, told Knobias on Tuesday, "The
VESTAsync(TM) technology is a drug eluting stent with a drug delivery technology that, unlike
its competitors, is made of substances that occurs naturally in the human body rendering it extremely
biocompatible and a promoter of expedited healing. Based on its numerous attributes
such as ultra thin struts, low coating thickness (0.6 microns making it over ten time thinner
than the thinnest drug eluting stent coating available today), and low drug dose (60% less
than Cypher) patients who receive VESTAsync should heal faster with 100% stent endothelial
coverage and acquire significantly less dual antiplatelet therapy than those receiving polymer
based drug eluting stents, which are the only one available today."
"No other company has taken a polymer free DES through FIM. Two companies (Atrium and
Biosensors) have started studies, but we will have to wait for results to see if they will be direct
competitors in the polymer free DES market. Companies that are selling polymer based drug
eluting stents include Johnson and Johnson, Abbott, Boston Scientific, Medtronic, Terumo,
Biosensors, and a number of smaller companies with me too technology."
VESTAsync was recently featured in Scientific American, an online science, health, and
technology source. According to the article, "...such devices are just as good as bare metal
stents at keeping arteries open and less likely than polymer-coated stents -- which typically
administer a drug to keep tissue growth at bay -- to contribute to blood clotting, irritation and
inflammation."
"We have developed a drug delivery system that can be used on stents and other implantable
medical devices that is polymer-free and can administer medication to the local tissue to keep
an artery from re-closing," the article quotes Dr. Landy. "Patients who receive drug-coated
polymer stents are generally required to take Plavix or another anticoagulant for at least a
year after an angioplasty, in addition to the medicine dispensed by the stents. MIV's goal is to
create a drug eluting stent with the safety profile and deliverability of a bare metal stent."
Dr. Landy explained to Knobias, "VESTAsync is not another me too drug eluting stent and
should not be tarnished with the same concerns that have plagued the first and second generation
of drug eluting stents. VESTAsync is a new concept aimed at combining bare metal
stent safety with drug eluting stent efficacy thereby eliminating all the drawbacks of current
drug eluting stents and rejuvenating the drug eluting stent market."

For the past seven years, the Company has funded operations in the
public markets. The Company does not currently have any development
partners other than The University of British Columbia who developed
the original technology.
Dr. Landy added, "We are not making any public comments at this time
regarding partnerships or potential partnerships. We have publicly announced
six products in angioplasty available for sale, including CE approved
bare metal stents. We are actively working on pipeline products
but have not made these public."
The Company announced on Monday that its board of directors approved
a one-for-10 reverse stock split of the company's approximately
116 million issued and outstanding common shares.
"We view the split as a positive move to benefit both the company and
its shareholders. It is expected to result in an increase in attractiveness
to institutional investors," commented Dr. Landy. He added, "The split
will also adjust the authorized and outstanding shares to a level better
suited to a company of our size."